On-target activity of neoadjuvant cixutumumab and combined androgen deprivation therapy for high-risk prostate cancer: A phase II trial. Background: Degarelix, a GnRH receptor antagonist inducing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback